Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Park, Yeon Hee; Kim, Tae-Yong; Kim, Gun Min; Kang, Seok Yun; Park, In Hae; Kim, Jee Hyun; Lee, Kyoung Eun; Ahn, Hee Kyung; Lee, Moon Hee; Kim, Hee-Jun; Kim, Han Jo; Lee, Jong In; Koh, Su-Jin; Kim, Ji-Yeon; Lee, Kyung-Hun; Sohn, Joohyuk; Kim, Sung-Bae; Ahn, Jin-Seok; Im, Young-Hyuck; Jung, Kyung Hae; Im, Seock-Ah; Ahn, HK; Cho, EK; Park, IH; Lee, KS; Sim, SS; Hong, SJ; Chang, MH; Kim, JH; Kim, YJ; Kim, SH; Suh, KJ; Park, YH; Park, WY; Choi, YL; Yu, JH; Im, YH; Ahn, JS; Hur, JY; Park, SH; Kim, JY; Nam, SJ; Lee, JE; Kim, SW; Lee, SK; Im, SA; Kim, MS; Kim, TY; Oh, DY; Kim, TY; Lee, KH; Lee, DW; Kim, HJ; Jung, KH; Kim, SB; Ahn, JH; Kim, JE; Jung, JH; Kang, SY; Ahn, MS; Choi, YW; Kim, GM; Sohn, JH; Kim, MH; Koh, SJ; Cheon, JK; Lee, JI; Lim, ST; Hyun, SY; Lee, KE; Kim, HJ; Lee, MH; Cho, JH; Lim, JH

期刊名称The Lancet Oncology
作者Park, Yeon Hee; Kim, Tae-Yong; Kim, Gun Min; Kang, Seok Yun; Park, In Hae; Kim, Jee Hyun; Lee, Kyoung Eun; Ahn, Hee Kyung; Lee, Moon Hee; Kim, Hee-Jun; Kim, Han Jo; Lee, Jong In; Koh, Su-Jin; Kim, Ji-Yeon; Lee, Kyung-Hun; Sohn, Joohyuk; Kim, Sung-Bae; Ahn, Jin-Seok; Im, Young-Hyuck; Jung, Kyung Hae; Im, Seock-Ah; Ahn, HK; Cho, EK; Park, IH; Lee, KS; Sim, SS; Hong, SJ; Chang, MH; Kim, JH; Kim, YJ; Kim, SH; Suh, KJ; Park, YH; Park, WY; Choi, YL; Yu, JH; Im, YH; Ahn, JS; Hur, JY; Park, SH; Kim, JY; Nam, SJ; Lee, JE; Kim, SW; Lee, SK; Im, SA; Kim, MS; Kim, TY; Oh, DY; Kim, TY; Lee, KH; Lee, DW; Kim, HJ; Jung, KH; Kim, SB; Ahn, JH; Kim, JE; Jung, JH; Kang, SY; Ahn, MS; Choi, YW; Kim, GM; Sohn, JH; Kim, MH; Koh, SJ; Cheon, JK; Lee, JI; Lim, ST; Hyun, SY; Lee, KE; Kim, HJ; Lee, MH; Cho, JH; Lim, JH
印刷ISSN1470-2045
文件大小323.17KB
发表时间2019-10
DOI10.1016/S1470-2045(19)30565-0

发现好书期刊，享受阅读乐趣

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial